PDL BioPharma (PDLI) : During the past 4 weeks, traders have been relatively bearish on PDL BioPharma (PDLI), hence the stock is down -10.16% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -14.57% relative to the S&P 500. The 4-week change in the price of the stock is -7.93% and the stock has fallen -14.21% in the past 1 week.
PDL BioPharma (NASDAQ:PDLI): The stock opened at $3.20 on Friday but the bulls could not build on the opening and the stock topped out at $3.24 for the day. The stock traded down to $2.87 during the day, due to lack of any buying support eventually closed down at $3.02 with a loss of -14.69% for the day. The stock had closed at $3.54 on the previous day. The total traded volume was 5,203,573 shares.
The stock has recorded a 20-day Moving Average of 12.3% and the 50-Day Moving Average is 8.58%. PDL BioPharma, Inc. has dropped 3.33% during the last 3-month period . Year-to-Date the stock performance stands at -12.04%.
PDL BioPharma (PDLI) : Currently there are 2 street experts covering PDL BioPharma (PDLI) stock. The most bullish and bearish price target for the stock is $4 and $4 respectively for the short term. The average price target of all the analysts comes to $3.75. The estimated standard deviation from the target is $0.35.
PDL BioPharma, Inc., manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. The Company provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. It is focused on intellectual property asset management, acquiring new income generating assets and maximizing value for its stockholders. The Company receives royalties on a number of marketed products that use its technology and it has liscensed a number of humanized antibody products in late-stage clinical trials. As of December 31, 2014, the Company received royalties on sales of the ten humanized antibody products, which include Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, Tysabri, Actemra, Gazyva and Entyvio.